Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU and Interferon-alfa-2b in Metastatic GI, Kidney, or Lung Cancer
NCT01658813Phase 2Completed
- Sponsor
- Western Regional Medical Center
- Start
- Jul 2012
- Primary completion
- Jul 2014
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil and interferon alfa-2b in gastrointestinal cancer and metastatic renal cell carcinoma (mRCC), sponsored by Western Regional Medical Center. Primary endpoint: Progression Free Survival at 2 years. Started Jul 2012; status: completed.
02
Drugs
fluorouracilinterferon alfa-2b
03
Conditions
gastrointestinal cancermetastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01658813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658813.